Advances in pediatric pulmonary arterial hypertension

Current Opinion in Cardiology

Volumn 27, Issue 2, 2012, Pages 70-81

  Ivy, Dunbar ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

children; endothelin receptor antagonists; phosphodiesterase 5; prostacyclin; pulmonary hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CELL THERAPY AGENT; ILOPROST; IMATINIB; MACITENTAN; NITRIC OXIDE; PROSTACYCLIN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; UNIPROST; VASODILATOR AGENT;

BLOOD VESSEL REACTIVITY; BODY HEIGHT; BODY WEIGHT; CATHETER INFECTION; CAVOPULMONARY CONNECTION; CHILDHOOD DISEASE; CHROMOSOME DISORDER; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EISENMENGER COMPLEX; GENETIC DISORDER; HEART CATHETERIZATION; HUMAN; HYPERTRANSAMINASEMIA; IDIOPATHIC DISEASE; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; INJECTION SITE DISCOMFORT; LOW DRUG DOSE; LUNG VASCULAR RESISTANCE; MONOTHERAPY; OXYGEN SATURATION; PATIENT COMPLIANCE; PREMATURITY; PRESYNCOPE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SLEEP DISORDERED BREATHING; SURVIVAL RATE; SYNCOPE; TRISOMY 21; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CHILD; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MORBIDITY; PHOSPHODIESTERASE 5 INHIBITORS; SURVIVAL RATE; WORLD HEALTH;

EID: 84856823296     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835018cd     Document Type: Review

References (79)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl.):S43-S54.
2. Van Loon RL, Roofthooft MT, van Osch-Gevers M, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009; 155:176 e1-182 e1.
3. Cerro MJ, Abman S, Diaz G, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011; 1:286-298.
4. Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007; 137:510-513. (Pubitemid 47441802)
5. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009; 95:312-317.
6. Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010; 103:66-74.
7. Van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124:1755-1764.
8. Berger RM, Beghetti M, Humpl T, et al. Clinical features of pediatric pulmonary hypertension: the Global Registry Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP). Lancet (in press). Baseline demographics of pulmonary hypertension in a large worldwide registry of pediatric pulmonary hypertension.
9. Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term PAH disease management. Circulation 2012; 125:113-122.
10. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96:1401-1406.
11. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl.):S78-S84.
12. Ivy DD, Rashid A. Chronic pulmonary hypertension. In: Munoz R, Morell V, da Cruz E, Carol Vetterly C, editors. Critical care of children with heart disease: basic medical and surgical concepts. London: Springer-Verlag; 2010. pp. 483-505.
13. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011; 37:665-677.
14. Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010; 157:528-532.
15. Abman SH, Ivy DD. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr 2011; 23:298-304.
16. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
17. Lammers AE, Adatia I, Cerro MJ, et al. Functional classification of pulmonary hypertension in children: report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011; 1:280-285.
18. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986; 89:497-503. (Pubitemid 16133708)
19. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110:660-665. (Pubitemid 39056263)
20. Atz AM, Adatia I, Lock JE, et al. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33:813-819.
21. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 2002; 106 (12 Suppl. 1):I76-81.
22. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103:544-548. (Pubitemid 32116239)
23. Barst RJ, Agnoletti G, Fraisse A, et al. Vasodilator testing with nitric oxide and/ or oxygen in pediatric pulmonary hypertension. Pediatr Cardiol 2010; 31:598-606.
24. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl.):S55-S66.
25. Carmosino MJ, Friesen RH, Doran A, Ivy DD. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg 2007; 104:521-527.
26. Friesen RH, Williams GD. Anesthetic management of children with pulmonary arterial hypertension. Paediatr Anaesth 2008; 18:208-216. (Pubitemid 351159917)
27. Hill KD, Lim DS, Everett AD, et al. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. Catheter Cardiovasc Interv 2010; 76:865-873.
28. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99:1197-1208.
29. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302.
30. Barst R. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? Int J Clin Pract Suppl 2010; 64:23-32.
31. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008; 160:5-9. (Pubitemid 352000590)
32. Ivy DD, Calderbank M, Wagner BD, et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol 2009; 30:823-829.
33. Ivy DD, Doran A, Claussen L, et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93:943-946. (Pubitemid 38429615)
34. Melnick L, Barst RJ, Rowan CA, et al. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Am J Cardiol 2010; 105:1485-1489.
35. Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 2009; 5:325-331.
36. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51:161-169.
37. Limsuwan A, Wanitkul S, Khosithset A, et al. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008; 129:333-338.
38. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-804. (Pubitemid 34229650)
39. Levy M, Celermajer DS, Bourges-Petit E, et al. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 2011; 158:584-588.
40. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99:696-698.
41. Rosenzweig E, Krishnan U, Takatsuki S, et al. Inhaled treprostinil in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183:A6143.
42. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903. (Pubitemid 34984638)
43. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73:372-382. (Pubitemid 36403597)
44. Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009; 7:225-233.
45. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008; 64:200-204.
46. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92:664-670.
47. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:697-704. (Pubitemid 41132700)
48. Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011; 38:70-77.
49. Ivy DD, Rosenzweig EB, Lemarie JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010; 106:1332-1338.
50. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68:948-955.
51. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebocontrolled study. Circulation 2006; 114:48-54. (Pubitemid 44305274)
52. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121:20-25.
53. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:529-535. (Pubitemid 41040298)
54. Ivy DD, Rosenzweig EB, Calderbank M, et al. Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181:A3330.
55. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157. (Pubitemid 41653106)
56. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100:267-273.
57. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154:379-384.
58. Humpl T, Reyes JT, Erickson S, et al. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. Cardiol Young 2011; 21:187-193.
59. Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006; 174:1042-1047. (Pubitemid 44684454)
60. Atz Am LA, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crisis. J Thorac Cardiovasc Surg 2002; 124:628-629.
61. Barst RJ, Ivy DD, Gaitin G, et al. A randomized, double-blind placebocontrolled, dose-ranging study of oral sildenafil citrate in the treatment of children with pulmonary arterial hypertension. Circulation 2012; 125:324-334.
62. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108 (Suppl. 1):II167-II173. (Pubitemid 37099949)
63. Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003; 29:1996-2003. (Pubitemid 37487135)
64. Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155:841-847.
65. Fraisse A, Butrous G, Taylor MB, et al. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 2011; 37:502-509.
66. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-2903.
67. Rosenzweig EB. Tadalafil for the treatment of pulmonary arterial hypertenson. Expert Opin Pharmacother 2010; 11:127-132.
68. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatricpulmonary arterial hypertension. Pediatr Cardiol (in press)
69. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353:1412-1413. (Pubitemid 41362714)
70. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182:1171-1177.
71. Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005; 96:442-450. (Pubitemid 40354538)
72. Stewart DJ, Zhao YD, Courtman DW. Cell therapy for pulmonary hypertension: what is the true potential of endothelial progenitor cells? Circulation 2004; 109:e172-e173.
73. Yeager ME, Nguyen C, Belechenko D, et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J 2012; 39:104-111.
74. Belik J. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr Opin Investig Drugs 2009; 10:971-979.
75. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36:792-799.
76. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33:785-792.
77. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011; 20:567-576.
78. Morrison K, Ernst R, Hess P, et al. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther 2010; 335:249-255.
79. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67:977-984